RedHill Biopharma (RDHL) Competitors $4.76 -0.14 (-2.86%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$4.76 +0.00 (+0.11%) As of 02/21/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends RDHL vs. JATT, DARE, XCUR, NAII, RNXT, LGVN, LVTX, TENX, CGTX, and FNCHShould you be buying RedHill Biopharma stock or one of its competitors? The main competitors of RedHill Biopharma include JATT Acquisition (JATT), Daré Bioscience (DARE), Exicure (XCUR), Natural Alternatives International (NAII), RenovoRx (RNXT), Longeveron (LGVN), LAVA Therapeutics (LVTX), Tenax Therapeutics (TENX), Cognition Therapeutics (CGTX), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry. RedHill Biopharma vs. JATT Acquisition Daré Bioscience Exicure Natural Alternatives International RenovoRx Longeveron LAVA Therapeutics Tenax Therapeutics Cognition Therapeutics Finch Therapeutics Group JATT Acquisition (NYSE:JATT) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Does the MarketBeat Community believe in JATT or RDHL? RedHill Biopharma received 427 more outperform votes than JATT Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformJATT AcquisitionN/AN/ARedHill BiopharmaOutperform Votes42766.82% Underperform Votes21233.18% Do institutionals and insiders have more ownership in JATT or RDHL? 48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 6.8% of RedHill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better valuation & earnings, JATT or RDHL? RedHill Biopharma has higher revenue and earnings than JATT Acquisition. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/ARedHill Biopharma$6.53M0.93$23.92MN/AN/A Is JATT or RDHL more profitable? RedHill Biopharma's return on equity of 0.00% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% RedHill Biopharma N/A N/A N/A Does the media prefer JATT or RDHL? In the previous week, RedHill Biopharma had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for RedHill Biopharma and 0 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.00 equaled RedHill Biopharma'saverage media sentiment score. Company Overall Sentiment JATT Acquisition Neutral RedHill Biopharma Neutral SummaryRedHill Biopharma beats JATT Acquisition on 5 of the 8 factors compared between the two stocks. Get RedHill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedHill BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.27M$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.5616.5114.19Price / Sales0.93304.55450.0276.60Price / Cash0.0165.6738.0134.95Price / Book0.126.717.644.63Net Income$23.92M$138.11M$3.18B$245.69M7 Day Performance-9.76%-2.54%-1.95%-2.68%1 Month Performance-26.84%-2.00%-0.23%-2.16%1 Year Performance-98.59%-5.04%16.69%12.90% RedHill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedHill Biopharma0.5728 of 5 stars$4.76-2.9%N/A-98.6%$6.27M$6.53M0.00210JATTJATT AcquisitionN/A$1.55+3.3%N/A-61.9%$26.74MN/A0.003Gap UpHigh Trading VolumeDAREDaré Bioscience1.808 of 5 stars$3.04-4.1%$24.00+689.5%-27.0%$26.45M$2.81M-5.1530News CoverageXCURExicure1.2717 of 5 stars$10.03-0.6%N/A+1,352.1%$26.14M$500,000.00-4.8550NAIINatural Alternatives International0.3762 of 5 stars$4.15-2.4%N/A-30.4%$25.73M$113.80M-2.88290Earnings ReportAnalyst ForecastRNXTRenovoRx1.9 of 5 stars$1.04+1.0%$9.00+765.4%-24.3%$24.96MN/A-1.826Gap DownHigh Trading VolumeLGVNLongeveron3.561 of 5 stars$1.67+6.4%$8.67+419.0%-70.5%$24.78M$1.89M-0.2720Upcoming EarningsNews CoveragePositive NewsLVTXLAVA Therapeutics2.9368 of 5 stars$0.94+0.8%$3.33+254.6%-50.9%$24.71M$7.35M-0.9160Gap UpTENXTenax Therapeutics1.9324 of 5 stars$7.20-1.4%$16.00+122.2%+55.2%$24.55MN/A0.009News CoverageGap UpCGTXCognition Therapeutics3.3265 of 5 stars$0.59+0.0%$8.30+1,306.5%-70.7%$24.52MN/A-0.6120News CoverageFNCHFinch Therapeutics GroupN/A$15.00-3.2%N/A+537.1%$24.09M$110,000.00-1.70190News CoverageHigh Trading Volume Related Companies and Tools Related Companies JATT Acquisition Competitors Daré Bioscience Competitors Exicure Competitors Natural Alternatives International Competitors RenovoRx Competitors Longeveron Competitors LAVA Therapeutics Competitors Tenax Therapeutics Competitors Cognition Therapeutics Competitors Finch Therapeutics Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RDHL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share RedHill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
